Trodelvy (sacituzumab govitecan) has a mean half-life of about 16 hours, meaning half the drug clears from your bloodstream roughly every 16 hours. Its active cancer-killing component, a compound called SN-38, has a slightly longer half-life of 18 hours. Using the standard pharmacologic rule of five half-lives to reach negligible levels, the drug conjugate itself drops to clinically insignificant amounts within about 3 to 4 days after your last infusion.
How the Drug Leaves Your Body
Trodelvy is an antibody-drug conjugate, which means it’s really two things bundled together: a targeting antibody that locks onto a protein called Trop-2 on cancer cells, and SN-38, the active chemotherapy payload it delivers. Once inside the body, the linker connecting these two components breaks apart, releasing SN-38 primarily in acidic environments like the interior of tumor cells.
After SN-38 is released and does its work, a liver enzyme converts it into a water-soluble form that can be flushed out through bile and urine. The antibody portion of the drug, like other antibodies, lingers a bit longer in the bloodstream, with a half-life of roughly 6 days. That means the antibody shell can take about 30 days to fully clear, though it carries no chemotherapy payload at that point and is not pharmacologically active on its own.
Why Clearance Speed Varies Between People
Not everyone processes Trodelvy at the same rate. The liver enzyme responsible for breaking down SN-38 is controlled by a gene called UGT1A1, and common genetic variations in this gene can slow the process considerably. About 10% of people of European descent and a higher percentage of people of African descent carry two copies of a variant called UGT1A1*28, which reduces the enzyme’s activity. People with this variant clear SN-38 more slowly, meaning the drug’s active component stays in their system longer and at higher concentrations.
This slower clearance isn’t just a pharmacologic detail. It translates into a meaningfully higher risk of side effects, particularly severe drops in white blood cell counts (neutropenia) and diarrhea. People who carry even one copy of the variant face moderately increased risk, while those with two copies face the highest risk. Your oncology team may order genetic testing for this variant, and dosing can be adjusted based on how well you tolerate treatment.
What the Clearance Timeline Means in Practice
While the chemotherapy component reaches negligible blood levels within a few days, the body’s recovery from the drug’s effects takes considerably longer. This is why Trodelvy is given on days 1 and 8 of a 21-day cycle: the dosing schedule allows time for healthy cells, particularly immune cells and gut lining, to recover between infusions.
Side effects like fatigue, nausea, and low blood counts can persist well beyond the point when the drug itself is undetectable in your blood. The cellular damage SN-38 causes takes time to repair, so feeling the effects for a week or more after an infusion is normal even though the compound is technically gone.
Safety Windows After Your Final Dose
Regulatory guidelines reflect a more cautious timeline than the drug’s raw half-life might suggest, because SN-38 can damage DNA in ways that outlast its presence in the bloodstream. Women of childbearing potential should use effective contraception during treatment and for 6 months after the last dose. Male patients with partners who could become pregnant should continue contraception for 3 months after the final dose. Breastfeeding should stop during treatment and not resume until at least 1 month after the last infusion.
These windows are substantially longer than the 3 to 4 days it takes for the drug to clear your blood because they account for lingering effects on egg cells, sperm development, and the potential for drug traces in breast milk at levels too low to measure easily but still potentially harmful to an infant.